Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effects on spirometric indices in COPD patients with type 2 diabetes
IRCT20191209045671N4Phase 3Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of empagliflozin in chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM), sponsored by Semnan University of Medical Sciences. Primary endpoints: FEV1, PEF and 2 more. Started Dec 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic obstructive pulmonary disease (COPD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20191209045671N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191209045671N4.